Compare Stocks: KRRO, PRME, ALLO, and CBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.50 -2.6%	$1.88	$1.04 ▼ $4.46	$518.24M	0.56	5.62 million shs	4.63 million shs
CBIO Crescent Biopharma	$14.32 +0.4%	$16.92	$8.72 ▼ $27.41	$531.90M	1.27	516,818 shs	283,270 shs
KRRO Korro Bio	$9.64 -0.7%	$11.96	$5.20 ▼ $55.89	$141.96M	3.13	201,577 shs	153,051 shs
PRME Prime Medicine	$2.98 -0.3%	$3.24	$2.67 ▼ $6.94	$540.50M	2.37	3.21 million shs	2.11 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-9.09%	-24.24%	-27.88%	+20.97%
CBIO Crescent Biopharma	0.00%	+2.36%	-29.80%	-16.21%	+20.34%
KRRO Korro Bio	0.00%	+0.73%	-17.04%	-31.14%	-78.04%
PRME Prime Medicine	0.00%	+2.76%	-19.68%	-23.00%	-46.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.50 -2.6%	$1.88	$1.04 ▼ $4.46	$518.24M	0.56	5.62 million shs	4.63 million shs
CBIO Crescent Biopharma	$14.32 +0.4%	$16.92	$8.72 ▼ $27.41	$531.90M	1.27	516,818 shs	283,270 shs
KRRO Korro Bio	$9.64 -0.7%	$11.96	$5.20 ▼ $55.89	$141.96M	3.13	201,577 shs	153,051 shs
PRME Prime Medicine	$2.98 -0.3%	$3.24	$2.67 ▼ $6.94	$540.50M	2.37	3.21 million shs	2.11 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-9.09%	-24.24%	-27.88%	+20.97%
CBIO Crescent Biopharma	0.00%	+2.36%	-29.80%	-16.21%	+20.34%
KRRO Korro Bio	0.00%	+0.73%	-17.04%	-31.14%	-78.04%
PRME Prime Medicine	0.00%	+2.76%	-19.68%	-23.00%	-46.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.79	Moderate Buy	$8.30	453.33% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	106.70% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	73.38% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	150.75% Upside

Current Analyst Ratings Breakdown

Latest KRRO, PRME, ALLO, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	PRME Prime Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/23/2026	ALLO Allogene Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/9/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	25,911.75	N/A	N/A	$1.30 per share	1.15
CBIO Crescent Biopharma	$10.84M	49.06	N/A	N/A	$14.32 per share	1.00
KRRO Korro Bio	$6.39M	22.22	N/A	N/A	$5.46 per share	1.77
PRME Prime Medicine	$4.63M	116.74	N/A	N/A	$0.67 per share	4.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	N/A	-114.26%	-68.57%	11/11/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A

Latest KRRO, PRME, ALLO, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
CBIO Crescent Biopharma	N/A	9.66	9.66
KRRO Korro Bio	N/A	9.55	9.55
PRME Prime Medicine	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CBIO Crescent Biopharma	75.19%
KRRO Korro Bio	13.18%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CBIO Crescent Biopharma	24.84%
KRRO Korro Bio	4.80%
PRME Prime Medicine	16.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
KRRO Korro Bio	57	14.73 million	14.02 million	No Data
PRME Prime Medicine	146	181.38 million	152.28 million	N/A

KRRO, PRME, ALLO, and CBIO Headlines

Recent News About These Companies

What kind of company is Prime Medicine (PRME)? — A gene-editing company where funding outlooks and data timelines "overlap"

October 3 at 12:18 PM | note.comN

Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen

October 3 at 1:17 AM | marketbeat.com

Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME

September 30, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1% - Still a Buy?

September 29, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Earns Buy Rating from Chardan Capital

September 27, 2026 | americanbankingnews.com

Prime Medicine Clears FDA Hurdle For Gene-Editing Therapy Targeting Rare Genetic Disease; Stock Up

September 26, 2026 | rttnews.com

Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says

September 26, 2026 | finance.yahoo.com

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

September 25, 2026 | seekingalpha.com

Prime Medicine (NASDAQ:PRME) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Keeps Buy Rating at Chardan Capital

September 25, 2026 | marketbeat.com

Prime Medicine, Inc.: Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

September 25, 2026 | finanznachrichten.de

Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application

September 24, 2026 | marketscreener.comM

Prime Medicine stock surges on FDA IND clearance

September 24, 2026 | finance.yahoo.com

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

September 24, 2026 | globenewswire.com

Prime Medicine (NASDAQ:PRME) Stock Price Down 7.5% - Should You Sell?

September 23, 2026 | marketbeat.com

Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts

September 22, 2026 | marketbeat.com

Gene-editing powerhouse and its rivals surge toward a breakout

September 17, 2026 | msn.com

Prime Medicine (NASDAQ:PRME) Shares Up 11.8% - Should You Buy?

September 17, 2026 | marketbeat.com

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Prime Medicine, Inc. (PRME) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

September 15, 2026 | seekingalpha.com

Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen

September 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRRO, PRME, ALLO, and CBIO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.50 -0.04 (-2.60%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.02 (+1.20%)

As of 10/2/2026 07:58 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Crescent Biopharma NASDAQ:CBIO

$14.32 +0.06 (+0.42%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$14.15 -0.17 (-1.17%)

As of 10/2/2026 07:57 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Korro Bio NASDAQ:KRRO

$9.64 -0.07 (-0.72%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.67 +0.03 (+0.27%)

As of 10/2/2026 07:30 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Prime Medicine NASDAQ:PRME

$2.98 -0.01 (-0.33%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.00 +0.02 (+0.50%)

As of 10/2/2026 07:55 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, PRME, ALLO, and CBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, PRME, ALLO, and CBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, PRME, ALLO, and CBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRRO, PRME, ALLO, and CBIO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Crescent Biopharma NASDAQ:CBIO

Korro Bio NASDAQ:KRRO

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, PRME, ALLO, and CBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, PRME, ALLO, and CBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, PRME, ALLO, and CBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRRO, PRME, ALLO, and CBIO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Crescent Biopharma NASDAQ:CBIO

Korro Bio NASDAQ:KRRO

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools